Skip to Content

Lastacaft Approval History

FDA Approved: Yes (First approved July 28, 2010)
Brand name: Lastacaft
Generic name: alcaftadine
Dosage form: Ophthalmic Solution
Company: Allergan plc
Treatment for: Conjunctivitis, Allergic

Lastacaft (alcaftadine ophthalmic solution) is a topical H1 histamine receptor antagonist indicated for the prevention of itching associated with allergic conjunctivitis.

Development History and FDA Approval Process for Lastacaft

DateArticle
Jul 28, 2010Approval FDA Approves Lastacaft (alcaftadine ophthalmic solution) for Prevention of Itching Associated with Allergic Conjunctivitis

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide